Last reviewed · How we verify
Seretide Evohaler
Seretide Evohaler is a combination of fluticasone and salmeterol, which work together to reduce inflammation and bronchospasm in the airways.
Seretide Evohaler is a combination of fluticasone and salmeterol, which work together to reduce inflammation and bronchospasm in the airways. Used for Chronic obstructive pulmonary disease (COPD), Asthma.
At a glance
| Generic name | Seretide Evohaler |
|---|---|
| Also known as | Reference product, Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI |
| Sponsor | FLUIDDA nv |
| Drug class | Corticosteroid and long-acting beta2-adrenergic receptor agonist combination |
| Target | Beta2-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Fluticasone is a corticosteroid that reduces inflammation in the airways, while salmeterol is a long-acting beta2-adrenergic receptor agonist that helps to relax the muscles in the airways, making it easier to breathe.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma
Common side effects
- Oral thrush
- Headache
- Cough
- Throat irritation
- Muscle cramps
Key clinical trials
- Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate (PHASE1)
- Explorative Clinical Investigation to Investigate the Ability of PreciseInhale to Direct Regional Lung Targeting and Reduce the Degree of Throat Deposition and Subsequent Gastrointestinal Absorption in Healthy Volunteers After Inhalation of Test Drug Substances Via the PreciseInhale System (NA)
- Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients (NA)
- Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers (PHASE4)
- A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer (PHASE1)
- Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler (PHASE4)
- Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma (PHASE2)
- Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Seretide Evohaler CI brief — competitive landscape report
- Seretide Evohaler updates RSS · CI watch RSS
- FLUIDDA nv portfolio CI